MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$59,265K
Free Cash flow
-$59,356K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Stock-based compensation expense
    • Inventory
    • Amortization of acquired intangi...
    • Others
Negative Cash Flow Breakdown
    • Accounts payable and accrued exp...
    • Accounts receivable
    • Change in fair value of investme...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
602
137,162
-5,397
-27,518
Depreciation expense
94
93
92
93
Loss on disposal of property and equipment
-
-
0
0
Bad debt expense
-11
30
-41
76
Amortization of debt discount
223
1,455
339
319
Accretion of partner company convertible preferred shares
-
-
0
0
Gain on termination of partner company lease
-
0
0
0
Loss on extinguishment of debt
-
-
0
0
Amortization of acquired intangible assets
969
1,126
1,065
3,193
Settlement of partner company payables
-33
-76
-731
-577
Reduction in the carrying amount of operating lease right-of-use assets
465
480
476
496
Stock-based compensation expense
2,878
1,756
2,459
3,198
Change in fair value of investment
10,744
1,047
0
15,075
Expense (income) associated with warrant liabilities
-
-
-
2
Common shares issued for dividend on partner company's convertible preferred shares
-
-
0
0
Change in fair value of partner company derivative liability
0
-7,085
-
-
Change in fair value of partner companies' warrant liabilities
0
-1
398
-
Research and development - licenses acquired, expense
-
-
0
-
Gain from deconsolidation of subsidiary
82
-
0
27,127
Asset impairment loss
-
-
0
0
Accounts receivable
11,243
-4,761
11,759
2,415
Inventory
-1,136
-332
-2,194
-1,034
Other receivables - related party
-10
358
16
-416
Prepaid expenses and other current assets
-958
-56
2,553
-1,744
Other assets
437
339
-21
-17
Accounts payable and accrued expenses
-43,628
45,937
2,678
-2,828
Income taxes payable
-239
5,062
-649
21
Lease liabilities
-535
-550
-552
-549
Other long-term liabilities
340
887
-169
-1,973
Net cash provided by (used in) operating activities
-59,277
203,851
-12,544
-6,110
Acquired intangible assets
-
-
0
-
Proceeds from sale of property and equipment
-
0
0
0
Net cash increase upon deconsolidation of subsidiary
-
-
0
8,956
Purchase of property and equipment
79
-
-
-
Net cash (used in) provided by investing activities
-79
0
0
2,870
Payment of series a perpetual preferred stock dividends
-
-
0
0
Proceeds from issuance of common stock for public offering, net
-
-
0
0
Proceeds from issuance of common stock for at-the-market offering, net
-
0
0
0
Proceeds from issuance of common stock under espp
74
0
44
0
Exercise of warrants for cash
0
1,218
368
1,686
Proceeds from partner companies' espp
0
148
0
118
Partner company's dividends declared and paid
-
0
166
166
Exchange of partner company preferred shares
0
165
-
-
Partner company's redemption of preferred shares
-
-
0
0
Redemption of partner company preferred shares
0
14,170
-
-
Proceeds from partner companies' equity offerings and warrant exercises, net
-
0
40
7,247
Proceeds from partner companies' at-the-market offering, net
-141
0
5,421
6,891
Proceeds from exercise of partner company's options, net
158
72
0
-
Repayment of oaktree note and debt issuance costs
0
14,494
55
574
Repayment of partner company installment payments - licenses
-
0
0
0
Stock and warrants issued for exchange of partner company preferred shares
-
-
0
0
Proceeds from long-term debt, net
-
-
55
-130
Proceeds from partner company's long-term debt, net
-
-
0
0
Net cash provided by (used in) financing activities
91
-27,391
5,707
15,072
Net increase in cash and cash equivalents and restricted cash
-59,265
176,460
-6,837
11,832
Cash and cash equivalents and restricted cash at beginning of period
257,061
80,601
87,438
58,815
Cash and cash equivalents and restricted cash at end of period
197,796
257,061
80,601
87,438
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from exercise ofpartner company's...$158K Proceeds from issuance ofcommon stock under espp$74K (72.09%↑ Y/Y)Net cash provided by(used in) financing...$91K (-99.84%↓ Y/Y)Canceled cashflow$141K Net increase in cashand cash...-$59,265K (-452.96%↓ Y/Y)Canceled cashflow$91K Stock-based compensationexpense$2,878K (-87.53%↓ Y/Y)Inventory-$1,136K (28.06%↑ Y/Y)Amortization of acquiredintangible assets$969K Prepaid expenses andother current assets-$958K (59.32%↑ Y/Y)Net income (loss)$602K Reduction in the carryingamount of operating...$465K (-52.11%↓ Y/Y)Other long-termliabilities$340K (-26.72%↓ Y/Y)Amortization of debt discount$223K (-70.11%↓ Y/Y)Depreciation expense$94K (-56.88%↓ Y/Y)Other receivables -related party-$10K (-102.58%↓ Y/Y)Proceeds from partnercompanies' at-the-market...-$141K (-102.09%↓ Y/Y)Net cash provided by(used in) operating...-$59,277K (-25.79%↓ Y/Y)Canceled cashflow$7,675K Net cash (used in)provided by investing...-$79K (-101.09%↓ Y/Y)Accounts payable andaccrued expenses-$43,628K (-457.83%↓ Y/Y)Accounts receivable$11,243K (117.59%↑ Y/Y)Change in fair value ofinvestment$10,744K Lease liabilities-$535K (52.44%↑ Y/Y)Other assets$437K (249.66%↑ Y/Y)Income taxes payable-$239K (-559.62%↓ Y/Y)Gain fromdeconsolidation of subsidiary$82K Settlement of partnercompany payables-$33K (95.85%↑ Y/Y)Bad debt expense-$11K (95.53%↑ Y/Y)Purchase of property andequipment$79K

Fortress Biotech, Inc. (FBIO)

Fortress Biotech, Inc. (FBIO)